Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SCYX
#3582
SCYNEXIS, Inc.
0.7
5
+4.17%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+4.17%
Mudança mensal
-6.25%
Mudança em 6 meses
-9.64%
Mudança anual
-25.00%
Fechamento anterior
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Volume
3
Mercados
Ações
Cuidados de saúde
SCYX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Notícias
SCYNEXIS doses first patients in SCY-247 IV formulation trial
FDA предоставляет ускоренный статус препарату SCYNEXIS
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
SCYNEXIS получает грант в $7 млн на исследование противогрибковых препаратов
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim снижает целевую цену акций SCYNEXIS до $3 после GSK
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS receives $22 million from GSK as MARIO study ends
Scynexis получит $24,3 млн от GSK после завершения исследования MARIO
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247